Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor
Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
To the Editor.—According to the American Society of Clinical Oncology recommendations,1 genetic testing for breast cancer should be performed when the a priori probability of finding a mutation is at least 10%. Based on this recommendation, recent articles in JAMA2,3 may affect BRCA1screening indications, since the observed detection mutation rates are lower than previously thought. The lowest rate can be attributed to the lack of power of the current screening methods, the low prevalence rate of BRCA1germline mutations in the populations now under study, or both.
Eisinger F, Noguès C, Birnbaum D, Jacquemier J, Sobol H. BRCA1and Medullary Breast Cancer. JAMA. 1998;280(14):1227-1228. doi:10.1001/jama.280.14.1227